Shark variable new antigen receptor biologics – a novel technology platform for therapeutic drug development
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Shark variable new antigen receptor biologics – a novel technology platform for therapeutic drug development
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 14, Issue 10, Pages 1527-1539
Publisher
Informa Healthcare
Online
2014-08-04
DOI
10.1517/14712598.2014.937701
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Thermal stability and refolding capability of shark derived single domain antibodies
- (2014) Jinny L. Liu et al. MOLECULAR IMMUNOLOGY
- Nanobody-based products as research and diagnostic tools
- (2014) Thomas De Meyer et al. TRENDS IN BIOTECHNOLOGY
- Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock
- (2013) Rafael Bojalil et al. BMC IMMUNOLOGY
- Certolizumab Pegol
- (2013) Emma D. Deeks DRUGS
- Camelid single-domain antibody-fragment engineering for (pre)clinicalin vivomolecular imaging applications: adjusting the bullet to its target
- (2013) Jens De Vos et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins
- (2013) A. Richter et al. FEBS LETTERS
- Atypical Antigen Recognition Mode of a Shark Immunoglobulin New Antigen Receptor (IgNAR) Variable Domain Characterized by Humanization and Structural Analysis
- (2013) Oleg V. Kovalenko et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Human TNF cytokine neutralization with a vNAR fromHeterodontus franciscishark: A potential therapeutic use
- (2013) Tanya Camacho-Villegas et al. mAbs
- scFv Antibody: Principles and Clinical Application
- (2012) Zuhaida Asra Ahmad et al. Clinical & Developmental Immunology
- Monoclonal antibody therapeutics: history and future
- (2012) Nicholas APS Buss et al. CURRENT OPINION IN PHARMACOLOGY
- Glomerular endothelium: A porous sieve and formidable barrier
- (2012) Marya Obeidat et al. EXPERIMENTAL CELL RESEARCH
- Variable domain antibodies specific for viral hemorrhagic septicemia virus (VHSV) selected from a randomized IgNAR phage display library
- (2012) Maki Ohtani et al. FISH & SHELLFISH IMMUNOLOGY
- RECRUIT-TandAbs®: harnessing the immune system to kill cancer cells
- (2012) Fionnuala McAleese et al. Future Oncology
- Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain
- (2012) Mischa R. Müller et al. mAbs
- Marketed therapeutic antibodies compendium
- (2012) Janice M. Reichert mAbs
- Construction of an Artificially Randomized IgNAR Phage Display Library: Screening of Variable Regions that Bind to Hen Egg White Lysozyme
- (2012) Maki Ohtani et al. MARINE BIOTECHNOLOGY
- Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
- (2012) M. E. Weinblatt et al. RHEUMATOLOGY
- Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept
- (2012) Thierry Wurch et al. TRENDS IN BIOTECHNOLOGY
- Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
- (2011) A. W. Tolcher et al. CLINICAL CANCER RESEARCH
- DARPins and other repeat protein scaffolds: advances in engineering and applications
- (2011) Ykelien L Boersma et al. CURRENT OPINION IN BIOTECHNOLOGY
- Non-immunoglobulin based protein scaffolds
- (2011) John Löfblom et al. CURRENT OPINION IN BIOTECHNOLOGY
- Isolation and characterisation of Ebolavirus-specific recombinant antibody fragments from murine and shark immune libraries
- (2011) Sarah A. Goodchild et al. MOLECULAR IMMUNOLOGY
- Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody
- (2011) Renae Walsh et al. VIROLOGY
- PEGylation of therapeutic proteins
- (2010) Simona JevsÌevar et al. Biotechnology Journal
- Dissection of the IgNAR V Domain: Molecular Scanning and Orthologue Database Mining Define Novel IgNAR Hallmarks and Affinity Maturation Mechanisms
- (2010) B.J. Fennell et al. JOURNAL OF MOLECULAR BIOLOGY
- The safety and side effects of monoclonal antibodies
- (2010) Trevor T. Hansel et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon
- (2010) A. Walker et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Adnectins: engineered target-binding protein therapeutics
- (2010) D. Lipovsek PROTEIN ENGINEERING DESIGN & SELECTION
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Engineered therapeutic antibodies with improved effector functions
- (2009) Tsuguo Kubota et al. CANCER SCIENCE
- Engineered protein scaffolds as next-generation antibody therapeutics
- (2009) Michaela Gebauer et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- FN3: a new protein scaffold reaches the clinic
- (2009) Laird Bloom et al. DRUG DISCOVERY TODAY
- Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
- (2009) Y. A. Yeung et al. JOURNAL OF IMMUNOLOGY
- Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
- (2009) Janusz Wesolowski et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
- (2009) M. M. Schmidt et al. MOLECULAR CANCER THERAPEUTICS
- Molecular engineering and design of therapeutic antibodies
- (2008) Leonard G Presta CURRENT OPINION IN IMMUNOLOGY
- Display scaffolds: protein engineering for novel therapeutics
- (2008) S NUTTALL et al. CURRENT OPINION IN PHARMACOLOGY
- Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery
- (2008) Andreas Lehmann EXPERT OPINION ON BIOLOGICAL THERAPY
- N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies
- (2008) Roland Stork et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
- (2008) L. J. Holt et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Protein therapeutics: a summary and pharmacological classification
- (2007) Benjamin Leader et al. NATURE REVIEWS DRUG DISCOVERY
- Shark IgNAR antibody mimotopes target a murine immunoglobulin through extended CDR3 loop structures
- (2007) David P. Simmons et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation